Next Article in Journal
Independent Negative Prognostic Role of TCF1 Expression within the Wnt/β-Catenin Signaling Pathway in Primary Breast Cancer Patients
Previous Article in Journal
GNAQ Q209R Mutations Are Highly Specific for Circumscribed Choroidal Hemangioma
Review

PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review

1
Department of Medical Oncology, Aix-Marseille University, Inserm U1068, CNRS UMR7258, Institute Paoli-Calmettes, 13009 Marseille, France
2
CRCM—Tumor Immunology Laboratory, Aix-Marseille University, Inserm U1068, CNRS UMR7258, Institute Paoli-Calmettes, 13009 Marseille, France
3
CRCM—Predictive Oncology Laboratory, Aix-Marseille University, Inserm U1068, CNRS UMR7258, Institute Paoli-Calmettes, 13009 Marseille, France
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(7), 1033; https://doi.org/10.3390/cancers11071033
Received: 31 May 2019 / Revised: 16 July 2019 / Accepted: 17 July 2019 / Published: 22 July 2019
Recently, the development of immunotherapy through the immune checkpoint blockade led to long-lasting responses in several types of cancers that are refractory to conventional treatments, such as melanoma or non-small cell lung cancer. Immunotherapy has also demonstrated significant improvements in various other types of cancers. However, breast cancer remains one of the tumors that have not experienced the explosion of immunotherapy yet. Indeed, breast cancer was traditionally considered as being weakly immunogenic with a lower mutational load compared to other tumor types. In the last few years, anti-PD1/PD-L1 (Programmed death-ligand 1) agents have been evaluated in breast cancer, particularly in the triple negative subtype, with promising results observed when delivered as monotherapy or in combination with conventional treatments. In this review, we will report the results of the most recent studies evaluating immune checkpoint inhibitors in breast cancer. In addition, we will discuss the concomitant development of possible biomarkers, which is required for improving the selection of patients with the highest probability of benefiting from these agents. View Full-Text
Keywords: breast cancer; immunotherapy; PD1; PDL1; triple-negative breast cancer breast cancer; immunotherapy; PD1; PDL1; triple-negative breast cancer
Show Figures

Figure 1

MDPI and ACS Style

Planes-Laine, G.; Rochigneux, P.; Bertucci, F.; Chrétien, A.-S.; Viens, P.; Sabatier, R.; Gonçalves, A. PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review. Cancers 2019, 11, 1033. https://doi.org/10.3390/cancers11071033

AMA Style

Planes-Laine G, Rochigneux P, Bertucci F, Chrétien A-S, Viens P, Sabatier R, Gonçalves A. PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review. Cancers. 2019; 11(7):1033. https://doi.org/10.3390/cancers11071033

Chicago/Turabian Style

Planes-Laine, Gabrielle; Rochigneux, Philippe; Bertucci, François; Chrétien, Anne-Sophie; Viens, Patrice; Sabatier, Renaud; Gonçalves, Anthony. 2019. "PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review" Cancers 11, no. 7: 1033. https://doi.org/10.3390/cancers11071033

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop